Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
RAPP 
Rapport Therapeutics, Inc. Common Stock (RAPP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: RAPP (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $51.71
1 Year Target Price $51.71
| 4 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -5.02% | Avg. Invested days 25 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.15B USD | Price to earnings Ratio 20.73 | 1Y Target Price 51.71 |
Price to earnings Ratio 20.73 | 1Y Target Price 51.71 | ||
Volume (30-day avg) 5 | Beta - | 52 Weeks Range 6.43 - 42.27 | Updated Date 10/17/2025 |
52 Weeks Range 6.43 - 42.27 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.2 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -20.14% | Return on Equity (TTM) -29.42% |
Valuation
Trailing PE 20.73 | Forward PE - | Enterprise Value 1067489724 | Price to Sales(TTM) - |
Enterprise Value 1067489724 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 46113305 | Shares Floating 21041781 |
Shares Outstanding 46113305 | Shares Floating 21041781 | ||
Percent Insiders 4.88 | Percent Institutions 89.69 |
Upturn AI SWOT
Rapport Therapeutics, Inc. Common Stock
Company Overview
History and Background
Rapport Therapeutics is a clinical-stage biotechnology company focused on discovering and developing precision medicines for patients suffering from disorders of the brain. Founded in 2022, it aims to address unmet needs in neurological and psychiatric diseases. The company recently went public in 2024.
Core Business Areas
- Discovery and Development: Focused on researching and developing novel, targeted therapeutics for neurological and psychiatric conditions.
Leadership and Structure
The leadership team comprises experienced professionals in drug discovery, clinical development, and business strategy. Specific details about the organizational structure are generally found in company filings and press releases.
Top Products and Market Share
Key Offerings
- RAP-219: A potentially first-in-class, selective positive allosteric modulator (PAM) of the u03b12/3 subtype of GABA-A receptors. Currently in clinical trials. Competitors include companies developing other GABA modulators for neurological disorders (e.g., Sage Therapeutics, Biogen).
Market Dynamics
Industry Overview
The biotechnology industry, specifically the segment focused on neurological and psychiatric disorders, is characterized by high R&D costs, regulatory hurdles, and significant unmet medical needs. There's a growing demand for novel therapies with improved efficacy and safety profiles.
Positioning
Rapport Therapeutics aims to be a leader in precision medicines for brain disorders, differentiating itself through its targeted approach and novel therapeutic candidates. It is positioning itself by identifying unique biological pathways and mechanisms relevant to specific patient populations
Total Addressable Market (TAM)
The TAM for neurological and psychiatric disorders is substantial, estimated to be in the tens of billions of dollars globally. Rapport is positioned to capture a share of this market by developing targeted therapies for specific patient subpopulations.
Upturn SWOT Analysis
Strengths
- Novel therapeutic targets
- Experienced leadership team
- Strong financial backing post-IPO
- Focus on precision medicine
Weaknesses
- Early-stage clinical development
- High R&D costs
- Regulatory risks
- Competition from established players
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Positive clinical trial results
- Advancements in diagnostic technologies
Threats
- Clinical trial failures
- Regulatory setbacks
- Competition from existing therapies
- Intellectual property disputes
Competitors and Market Share
Key Competitors
- SAGE
- BIIB
- LLY
Competitive Landscape
Rapport Therapeutics competes with established pharmaceutical companies and other biotechnology firms in the neurological and psychiatric disorders space. Its competitive advantage lies in its targeted approach and novel therapeutic candidates.
Growth Trajectory and Initiatives
Historical Growth: Limited historical growth data due to recent IPO.
Future Projections: Future growth depends on the success of clinical trials and regulatory approvals. Analyst estimates will become available as the company progresses through its development pipeline.
Recent Initiatives: Focus on advancing lead compounds through clinical trials, expanding the pipeline with new therapeutic targets, and building strategic partnerships.
Summary
Rapport Therapeutics is a newly public biotech company focused on precision medicines for brain disorders. It has a promising pipeline of novel therapeutics, but faces the typical challenges of early-stage drug development, including clinical trial risk and competition. The company's financial position is strong post-IPO, providing resources to advance its programs. Its success hinges on demonstrating clinical efficacy and securing regulatory approvals.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
- Analyst reports (when available)
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be made based on individual risk tolerance and due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Rapport Therapeutics, Inc. Common Stock
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2024-06-07 | CEO, President, Treasurer & Director Mr. Abraham N. Ceesay M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 69 | Website https://www.rapportrx.com |
Full time employees 69 | Website https://www.rapportrx.com | ||
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. The company also develops RAP-199, a TARPy8 targeted molecule with differentiated chemical and pharmacokinetic properties; and nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and a9a10 nAChR for the treatment of hearing disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is based in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.